TG4010: A therapeutic vaccine against MUC1 expressing tumors.

Oncoimmunology ·第 1 卷 ·第 5 期 ·0000-00-00

Limacher Jean-Marc, Quoix Elisabeth

摘要

TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.

文献信息

期刊

Oncoimmunology

期刊简称

Oncoimmunology

ISSN

2162-4011

发表日期

0000-00-00

收录日期

2012-09-14

更新日期

2012-09-14

语言

英语

国家/地区

United States

NLM ID

101570526

外部链接

PubMed 原文

分析服务

TG4010: A therapeutic vaccine against MUC1 expressing tumors.

联系地址

微信公众号